NEW YORK (GenomeWeb) – Opko Health said this week that it has launched sales of its 4Kscore prostate cancer risk test in additional European territories.
Opko launched the test through its wholly owned subsidiary, Opko Health Spain in partnership with Barnaclínic, a branch of Hospital Clínic de Barcelona. The release follows the US launch of the test earlier this year and a 2012 European launch covering the UK, Ireland, Sweden, and Denmark.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
